2006
DOI: 10.1016/j.lungcan.2006.07.020
|View full text |Cite
|
Sign up to set email alerts
|

Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
5
0

Year Published

2008
2008
2014
2014

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 41 publications
0
5
0
Order By: Relevance
“…This was received by 51.6% of patients, which increased to 77.3% in the case of SCLC. There is a generalized increasing trend to use chemotherapy treatment in LC, either on its own or combined with other therapeutic options, being based on studies which have demonstrated a clinical benefit with this in detriment to palliative treatments (Trodella et al 2006). The surgery was performed in a low percentage of patients in our series, probably related to the large number of patients who were diagnosed for the first time in advanced stages and the high comorbidity they had at the time of diagnosis.…”
Section: Discussionmentioning
confidence: 96%
See 1 more Smart Citation
“…This was received by 51.6% of patients, which increased to 77.3% in the case of SCLC. There is a generalized increasing trend to use chemotherapy treatment in LC, either on its own or combined with other therapeutic options, being based on studies which have demonstrated a clinical benefit with this in detriment to palliative treatments (Trodella et al 2006). The surgery was performed in a low percentage of patients in our series, probably related to the large number of patients who were diagnosed for the first time in advanced stages and the high comorbidity they had at the time of diagnosis.…”
Section: Discussionmentioning
confidence: 96%
“…This was received by 51.6% of patients, which increased to 77.3% in the case of SCLC. There is a generalized increasing trend to use chemotherapy treatment in LC, either on its own or combined with other therapeutic options, being based on studies which have demonstrated a clinical benefit with this in detriment to palliative treatments (Trodella et al. 2006).…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, gemcitabine dosage in the concurrent chemoradiotherapy schedule was 600 mg/m 2 [6], which was nearly twice the recommended dosage in phase I studies [7]. Furthermore, in more recent reports, the weekly gemcitabine dosage concurrently with involved-field radiotherapy have been shown to be associated with low and acceptable toxicity [8, 9]. …”
Section: Predisposing Factors For Radiation-induced Esophagitismentioning
confidence: 99%
“…Chemotherapy helps radiotherapy to reduce the number of tumor cells by an average logarithm of 2-3 52 . Several studies have reported induction chemotherapy response rate ranging from 46% to 82% [53][54][55] . So, in selected bulky disease, induction chemotherapy can be useful to reduce the radiotherapy target volume, which is strictly correlated with toxicity.…”
Section: Chemotherapy For Nsclcmentioning
confidence: 99%